NASDAQ:NRIX Nurix Therapeutics Q3 2025 Earnings Results & Report $15.58 -0.03 (-0.16%) As of 02:29 PM Eastern This is a fair market value price provided by Massive. Learn more. Nurix Therapeutics missed analyst expectations on both earnings and revenue in its Q3 2025 results, released October 9, 2025. The company reported EPS of -$1.03 versus the -$0.84 consensus estimate, while revenue of $7.89 million fell short of the $16.06 million estimate by $8.17 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateOctober 9, 2025TimeBefore Market OpensConference Call4:00 PM ET Nurix Therapeutics EPS ResultsActual EPS-$1.03Consensus EPS -$0.84Beat/MissMissed by -$0.19One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersNurix Therapeutics Revenue ResultsActual Revenue$7.89 millionExpected Revenue$16.06 millionBeat/MissMissed by -$8.17 millionYoY Revenue GrowthN/AUpcoming EarningsNurix Therapeutics' Q4 2026 earnings is estimated for Wednesday, January 27, 2027, based on past reporting schedules, with a conference call scheduled on Thursday, January 28, 2027 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Nurix Therapeutics Q3 2025 Earnings FAQ Did Nurix Therapeutics beat earnings estimates for Q3 2025? Nurix Therapeutics (NASDAQ:NRIX) reported earnings of -$1.03 per share for Q3 2025, missing the consensus estimate of -$0.84. The report was announced on Thursday, October 9, 2025. What was Nurix Therapeutics' revenue for Q3 2025? Nurix Therapeutics reported revenue of $7.89 million for Q3 2025, against a consensus estimate of $16.06 million. When is Nurix Therapeutics' next earnings date? Nurix Therapeutics' next earnings date is estimated for Wednesday, January 27, 2027. MarketBeat tracks confirmed and estimated earnings dates for Nurix Therapeutics on the company's earnings history page. Nurix Therapeutics Earnings HeadlinesNurix Appoints Arati Rao As Chief Medical Officer To Lead Clinical DevelopmentNovember 11 at 12:48 AM | rttnews.comNurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical OfficerNovember 11 at 7:00 AM | globenewswire.comBeginner’s Guide to GoldThe Ultimate Beginner's Guide to Gold IRAs Protect Your Retirement Savings Before It's Too Late With This Informative Guide! Plus, you could even get up to 10% INSTANT MATCH in BONUS Silver (while supplies last).November 13 at 1:00 AM | Goldco Direct, LLC (Ad)Nurix Therapeutics to Participate in Upcoming Investor ConferencesNovember 10 at 7:00 AM | globenewswire.comNurix Therapeutics (NASDAQ:NRIX) Stock Breaks Below Two Hundred Day Moving Average Following Insider SellingNovember 6, 2026 | americanbankingnews.comNurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and ...November 5, 2026 | markets.businessinsider.comSee More Nurix Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nurix Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nurix Therapeutics and other key companies, straight to your email. Email Address About Nurix TherapeuticsNurix Therapeutics (NASDAQ:NRIX) is a clinical-stage biopharmaceutical company based in San Francisco, California. Founded in 2009, it develops medicines that aim to treat cancer and other diseases by changing the levels of specific proteins inside cells. The company’s technology focuses on protein degradation, using the cell’s natural protein-disposal system to remove disease-related proteins. Nurix also researches ways to regulate protein activity through ubiquitin signaling, a process that helps control how proteins function and are broken down. Nurix’s pipeline includes investigational drug candidates, including BTK degraders being studied for B-cell cancers and candidates designed to affect immune-cell signaling. The company has also pursued research and development collaborations with pharmaceutical partners. Its medicines remain under investigation and are not established treatments.View Nurix Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense OpportunityThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid? Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
